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Abstract
The burden of cancer is increasing worldwide, with a continuous rise of the annual total 
cases. Although mortality rates due to cancer are declining in developed countries, the 
total number of cancer deaths continues to rise due to the increase in the number of aged 
people. Three main causes of cancer have been described, represented by environmental 
factors, hereditary factors and random factors related to defects originated during cell 
replication. The frequency of cancers is very different for the various tissues and there 
is great debate on the extent of the specific contribution of environmental factors and 
random factors (due to “bad luck”) to cancer development. However, there is consensus 
that about 50% of all cases of cancer are related to environment and are preventable. 
Although a part of cancers is related to intrinsic mechanisms non preventable of ge-
netic instability, it is evident that implementation of primary and secondary prevention 
measures is the only affordable strategy to meet from a medical and economic point of 
view the tremendous pressure created on healthcare structures by the increased cancer 
burden. It is time to bypass the paradox of disease prevention: celebrated in principle, 
resisted in practice.
INTRODUCTION
In the last decades significant progresses in under-
standing of cancer etiology, cellular and molecular 
mechanisms involved in its development, early diagnosis 
and treatment and prevention have led to a significant 
decline in cancer mortality in industrialized world, as ev-
idenced by the 25% decline in the cancer mortality rate 
since 1991 [1]. However, the cancer burden remains 
very high, with more than 1.76 million new diagnosed 
cases and 606 000 cancer death projected to occur in 
2019 in the United States [2]. Over the past decade, the 
cancer incidence rate was stable in women and declined 
by about 2% per year in man; the cancer death rate de-
clined annually by 1.4% in women and 1.8% in men [2]. 
Comparable estimations have been made in Europe. 
Cancer incidence for men in 2018 in Europe, excluding 
non-melanoma skin cancer, was estimated as 436/100 
000, while for woman the estimated incidence rate was 
333/100 000 [3]. The total cases of cancer for 2018 were 
estimated to reach 3.91 million, with 1.93 million Euro-
peans dying cancer [3]. Mortality rates are declining in 
most European countries, but the total number of can-
cer deaths continues to rise, due to an increase of older 
people in the age range where cancer incidence is higher 
[3]. The analysis of worldwide cancer incidence in 2018 
provided by the International Agency for Research on 
Cancer (GLOBOCAN 2018) provided an estimation 
of 18.1 million new cancer cases and 9.6 million can-
cer deaths in 2018 [4]. The combined analysis to date 
on men and women showed that the most diagnosed 
(11.6% of total cases) and the most lethal (18.4% of to-
tal deaths) was lung cancer followed by female breast 
cancer (11.6%), prostate cancer (7.1%) and colorec-
tal cancer (6.1%) for incidence and colorectal cancer 
(9.2%), stomach cancer (8.2%) and liver cancer (8.2%) 
for mortality [4]. Lung cancer is the most frequent cause 
of death among men, while among women breast cancer 
is the most frequent for incidence and for mortality [4]. 
However, the most frequently diagnosed and the most 
lethal cancers substantially vary across countries [4]. 
Address for correspondence: Ugo Testa, Dipartimento oncologia e medicina molecolare, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 
Rome, Italy. E-mail: ugo.testa@iss.it.
























As it is well known, cancer incidence is related to 
age. In a recent annual report on the status of cancer 
in USA during the period 2011-2015, it was reported 
in adults ages 20-49 an overall cancer incidence among 
males of 115 per 100 000 and among females of 203 
per 100 000, compared to an incidence for all ages of 
494 among men and 420 among women [5]. In this 
age range, the most frequent cancer among males 
were colorectal, testis and melanoma of the skin, while 
among females were breast, thyroid and melanoma of 
the skin [5]. Extensive efforts over the last decades have 
been dedicated to the study of risk factors for the devel-
opment of cancer. These studies have led to identify two 
different types of risk factors: (a) unmodifiable intrinsic 
risk factors, defined as unavoidable spontaneous muta-
tions, occurring as a result of spontaneous, random ge-
netic errors in DNA replication and that must be con-
sidered as a typical feature of the biology of humans. 
These unavoidable DNA replication processing errors 
must be regarded as an intrinsic risk related to life. (b) 
non-intrinsic risk englobes two different types of error 
risks: (i) modifiable exogenous/external factors, such as 
carcinogens, xenobiotic and viruses, and lifestyle fac-
tors, such as smoking, nutrient intake, physical activity 
and hormone therapy that are completely exogenous to 
the host; (ii) endogenous factors that are related to pe-
culiar individual characteristics and that can be in part 
modified, such as immune response, metabolism, DNA 
damage response and hormone levels [6].
The identification of modifiable risk factors with 
strong or sufficient evidence was of fundamental im-
portance for the proposal of preventive measures. The 
main modifiable risk factors with strong evidence are 
represented by: (a) lifestyle factors, (physical inactiv-
ity, ultraviolet radiation exposure, cigarettes smok-
ing, second hand smoke and excess body weight); (b) 
alimentation (alcohol intake, low consumption of fruit 
and vegetables, dietary fiber, consumption of red and 
processed meat, dietary calcium); (c) infective agents 
(Helicobacter pylori, hepatitis B virus, hepatitis C virus, 
human herpes virus type 8, human immunodeficiency 
virus, human papillomavirus). The impact of modifiable 
risk factors on cancer development is very high and this 
supports the need for active cancer prevention. In this 
context, it is remarkable the study of Doll and Peto in 
1981 on the causes of cancer, showing that the tobacco 
was responsible for about 30% of cancer deaths in the 
United States [7]. In 1996, the American Cancer So-
ciety (ACS) issued a challenge objective to halve the 
cancer mortality observed in 1990 by 2015 through pre-
ventive measures, improvement in early diagnosis and 
treatment. In 2016, it was published a summary evalu-
ation of type ACS challenge goal, showing a 26% de-
cline in the overall US mortality for all cancers [8]. The 
mortality rates declined particularly for lung cancer, 
colorectal cancer, breast cancer and prostate cancer [8].
In 2019, it was proposed a new challenge goal on can-
cer mortality reduction, to be achieved in 2035, with 
the specific aim of reduction cancer mortality of 40% 
from the 2015 level [9]. A risk prevalence estimates car-
ried out in 2014 in the adult US population provided 
evidence that a 42% estimated incidence of all cancers 
and 45% of all cancer deaths are attributable to high-
risk environmental factors [10]. Among the various risk 
factors, cigarettes smoking accounted for the highest 
proportion of cancer cases and mortality, followed by 
excess body weight and alcohol intake (Table 1). Lung 
cancer displayed the highest number of cancer cases 
and deaths attributable to high risk factors, followed 
by colorectal cancer (Table 1). Some cancers, such as 
cervical cancer, melanoma, larynx, oral/pharyngeal and 
esophageal cancer have a very high proportion of cases 
attributable to risk factors (Table 1). 
THE THEORY OF BAD LUCK OF CANCER 
DEVELOPMENT
The development of cancer is related to progressive 
and gradual accumulation of driver gene mutations 
that confer a survival and proliferation advantage [11]. 
Initiating truncal mutations play a key role in tumor 
formation by enhancing the survival of the initiating 
cancer cells and by selecting for secondary mutations 
that play a significant role in tumor development and 
progression; these secondary mutations usually have 
some tissue-specificities [12]. Three types of mecha-
nisms are responsible of mutations observed in cancer. 
A first cause of mutations (E mutations) is related to 
environmental factors, as supported by numerous epi-
demiological studies [13]. A second cause of mutations 
is directly related to hereditary factors (H mutations), 
as supposed by the identification of genes responsible 
for cancer predisposition syndrome (frequently involv-
ing gene polymorphisms at the level of tumor suppres-
sor genes) and twin studies (these studies have shown 
in twins the existence of consistent familial risks that 
were higher in monozygotic than dizygotic twins) [14]. 
A third source of mutations causing cancer was related 
to random genetic mistakes (R mutations) occurring 
during DNA replication, a finding explaining why can-
cers are much more frequently observed in some tissue 
than other ones [15]. 
In 2015 Tomasetti and Vogelstein proposed a hy-
pothesis to explain variation in cancer risk among tis-
sues, based on the observation that there is a very good 
relationship between the number of stem cell division 
in the lifetime of a given tissue and the lifetime risk of 
developing cancer in that tissue [15]. According to this 
hypothesis, it was suggested only a third of the varia-
tion in cancer risk among tissues is attributable to en-
vironmental factors, while the majority is due to “bad 
luck”, consisting in random mutations occurring during 
DNA replication in normal tissue stem cells [15]. This 
hypothesis is supported by studies on the mutational 
risk of stem cells, related to their proliferative activity. 
It was estimated that three mutations occur every time 
a stem cell divide and that the number of mutations in 
tumors of self-renewing tissues is positively correlated 
with the age of patients at diagnosis [16].
A second support to this theory derives from the 
study of mouse model strongly supporting the conclu-
sion that tumor incidence in various mouse organs is 
dictated by the life-long generative capacity of mutat-
ed cells;  this finding supports the view that stem cells 
dictate organ cancer risk. Furthermore, in this study it 
























was shown that damage-induced activation of stem cell 
function markedly increases cancer risk [17].
A third strong support is issued from studies on clonal 
hematopoiesis, a common process in which somatically 
mutated hematopoietic stem cells (HSCs) generate 
a genetically distinct subpopulation in the blood; this 
phenomenon is estimated to increase with age and to 
occur in > 10% of the old subjects (> 70 years) [18]. The 
mutations occur in HSCs and frequently affect genes, 
such as DNMT3A, TET2, ASXL1, JAK2 and TP53, fre-
quently mutated in acute leukemias [18]. 
The findings initially proposed in 2015 were further 
extended by Tomasetti and coworkers in 2017, provid-
ing evidence that there is a very good direct correlation 
between the number of stem cell divisions and the risk 
of 17 cancer types in 69 countries in the world regard-
less of their different environment [19]. This theory im-
plies that the three potential sources of mutations (E, 
H and R) differently contribute to the various cancer 
types. In cancers, such as lung adenocarcinomas, R 
mutations contribute about a third of total mutations, 
with tobacco smoke and other environmental factors 
contributing the remainder. In cancers less strongly 
associated with environmental determinants, such as 
pancreas, brain or prostate cancers, the proportion of 
the mutations attributable to R mutations is more con-
sistent [19]. 
This hypothesis on cancer development was called 
“bad luck” hypothesis and was the focus of an inten-
sive debate, particularly for that concerns the relative 
contribution of intrinsic and extrinsic factors in cancer 
development. In this context, Wu et al. argued that er-
rors, occurring during the divisions of stem cells can be 
influenced by both intrinsic (mutations due to random 
errors in DNA replication) and extrinsic factors (envi-
ronmental factors, such as UV radiation, ionizing ra-
diation and carcinogens, that affect mutagenesis rate) 
[20]. These authors have quantified the relative role of 
extrinsic and intrinsic factors in lifetime cancer risks, 
reaching the conclusion that the contribution of intrin-
sic factors due to “bad luck” is less significant than pro-
posed by Tomasetti and coworkers [20].
Studies by high-throughput sequencing techniques 
add additional elements to the debate on the bad luck 
theory of cancer development. Alexandrov et al through 
the analysis of sequencing of more than 10 000 cancer 
genomes, have defined algorithms to assess different 
categories of somatic mutations and have thus identi-
fied 33 mutational signatures [21, 22]. Only for two of 
these signatures, 1 and 5, representing 23% of total mu-
tations, the number of mutations increased with age in 
26 out of 36 cancer types assessed. Cancer types char-
acterized by these two signatures include several tissue 
types associated with high proliferative rates, in line 
with the hypothesis that replication-associated defects 
are very relevant in these tumors [21, 22]. After removal 
of these signatures from all datasets, in the remaining 
77% of cases there was no correlation between age and 
number of mutations, thus supporting the view that for 
these tumors the role of replicative defects may be low, 
while the role of environmental factors is high [21, 22].
In a recent study, Perduca et al have replied to Toma-
setti and Vogelstein in a very provocative way indicating 
that the claim that cancer is mostly explained by intrin-
sic random factors is unsupported by data and theoreti-
cal models [23]. Very provocatively, they showed that 
smoking-induced mutations are more predictive of can-
cer risk than the lifetime number of stem cell divisions 
[23].
In addition to the cumulative number of previous 
Table 1
Major cancer risk factors, their incidence in cancer development and types of cancers etiologically related to these risk factors
Cancer risk factor Cancer 
incidence (%)
Type of cancers
Cigarette smoking 20-30 lung, larynx, esophagus, oral cavity, urinary bladder, liver, cervix, kidney, stomach, 
colorectum, liver, acute myeloid leukemia
Excessive body weight 8-10 endometrium, esophagus, liver, stomach, meningioma, multiple myeloma, 
pancreas, colorectum
Alcohol intake 5-10 mouth, pharynx, larynx, esophagus, liver, colorectum, female breast
Poor diet
Processed meats and red meats
Low vegetables and fruits
Low whole grains diet (low fiber diet)
4
colorectum cancer
mouth, pharynx, larynx, esophagus, stomach
colorectum cancer















cervix, anus, oropharynx, vagina, vulva, penis
stomach, gatric lymphoma
liver cancer, non-Hodgkin lymphoma
liver cancer, non-Hodgkin lymphoma
kaposi sarcoma, non-Hodgkin lymphoma, cervix, anus, Hodgkin lymphoma
Hodgkin lymphoma, non-Hodgkin lymphoma, Burkitt lymphoma, nasopharynx
Secondhand smoke 3 lung
























stem cell divisions within each tissue, also the degree 
of aberrant age-dependent methylation in normal tis-
sues correlates with lifetime risk of cancer development 
[24]. In fact, Klutstein et al. have explored the contri-
bution of epigenetic mechanisms to variation in can-
cer risk, supported by various observations indicating 
that abnormal methylation in normal tissues precedes 
the onset of tumor development, as shown by studies in 
colon crypts, skin and hematopoietic cells [24]. Particu-
larly, they showed that the degree of aberrant CpG is-
land DNA methylation in normal cells in various tissue 
correlates with the lifetime cancer risk [24]. This DNA 
methylation modification affects genes that control cell 
differentiation and act as driver genes in the tumors of 
various tissues [24].
Although the debate on the contribution of extrinsic 
or intrinsic factors as determinants of the mutations at 
the level of stem cells continues to spread in the sci-
entific literature, the theory of cancer development 
related to stem cell divisions was very stimulating and 
received further strong support by recent studies of se-
quencing of human normal tissues at the level of whole 
tissue or of the stem cell compartment. Martincorena 
et al., through sequencing of normal of healthy skin and 
esophagus, have shown that aging was associated with 
the colonization of these tissues by mutant clones of 
cells carrying driver mutations in typical cancer genes 
[25, 26]. These findings were confirmed by Yokoyama 
et al., who, through the analysis of a large number of 
esophageal biopsies, reached evidence on the progres-
sive age-related expansion of clones that carry mutations 
in driven genes (mostly NOTCH1), which is clearly ac-
celerated by smoking and alcohol consumption [27]; 
intriguingly, several mutations can be acquired before 
adolescence, even during infancy [27]. Yizhak and co-
workers have performed a large-scale analysis on 29 
normal human tissues and observed that genetic clones 
carrying somatic mutations are detected across normal 
tissues to different extents for the various tissues; these 
tissue-specific differences are related to both extrinsic 
factors (environmental influences) and intrinsic factors 
(natural tissue architecture, proliferation rate and the 
microenvironment) [28]. Importantly, cell prolifera-
tion was associated with the number of mutations [28]. 
According to these observations it was concluded that 
both aging and exposure to mutagenic factors contrib-
ute to the number of accumulated mutations in normal 
tissue, particularly in tissue with high cell proliferation 
rates [28]. Importantly, some of the clones observed in 
normal tissues may be the results of genetic drift, while 
other clones may develop under the effect of a positive 
selection driven by some mutational events [28]. Us-
ing an advanced single-cell whole-genome sequencing 
method, it was characterized the mutational landscape 
of human B lymphocytes in function of age, providing 
evidence that mutations were found to increase with 
age, with mutational signatures comparable to those 
observed in B cell leukemias [29]. The study of the mu-
tational spectrum observed in normal human hemato-
poietic cells has allowed to propose a reconstruction of 
the clonal dynamics of hematopoiesis during lifetime. 
In normal blood cells, the burden of somatic mutations 
progressively increases during aging and represents an 
accurate molecular clock [30].
A mutation arisen in a cell is inherited by its descen-
dant cells, a finding that allowed the reconstruction of 
normal hematopoietic development. Thus, the study of 
mutation allowed to predict the population dynamics 
of normal human hematopoiesis, involving a number of 
HSCs in the range of 50 000-200 000 [31].
Whole genome sequencing of normal human blood 
from many normal adults allowed to identify mutations 
occurring during human embryonic life and to estimate 
that approximately three point mutations occur per 
cell-doubling event [32].
Another study allowed to show that during aging 
mutations accumulate in HSCs and hematopoietic pro-
genitors at the same rate and it was estimated that these 
mutations accumulate at the rate of about 14 base sub-
stitutions per year [33].
Other recent studies have evaluated the accumula-
tion of mutations in some types of human adult stem 
cells during life. Thus Blokzijl, et al. have evaluated 
the mutational patterns in adult stem cells of the small 
intestine, colon and livers of donors corresponding to 
different, ages [34]. Mutations accumulate over tissue 
in all these three tissues, at a rate of approximately 40 
novel mutation per year, despite the consistent differ-
ences in cancer incidence among these tissues [34]. 
However, the mutational spectrum was different in the 
adult stem cells of these tissues, with small intestine and 
colon characterized by a mutational signature involving 
the spontaneous deamination of methylated cytosine 
residues (reflecting their high stem cell division rate) 
and liver with a different mutational signature charac-
terized by T to C transitions [34]. The same authors 
have investigated the mutation accumulation during 
human fetal development, providing evidence that mu-
tation accumulation rates in fetal stem cells are higher 
than in adult stem cells of the same organ [35]. This 
observation suggests that the rapid cellular expansion 
required to sustain fetal development comes at the cost 
of an increased mutation risk, causing mutation accu-
mulation [35].
The sequencing studies performed on normal tissues 
have provided impressive data, of fundamental impor-
tance for a better understanding of cancer develop-
ment. In this context, particularly important were the 
results of the study of Yizhak, et al. [28], carried out 
on 29 normal tissue types: clonal cell populations were 
found in tissues from the large majority (15%) of the 
488 individuals analyzed in this study; 40% of the tis-
sue samples analyzed contained at least one large muta-
tional clonal population and a minority of these clones 
were potentially pathological [28]. This study, as well 
as the other studies above reported on the sequencing 
of normal tissues/stem cell raise the important problem 
of the definition of normality. Importantly, the study 
of Yizhak, et al. [28] showed also that the endogenous 
proliferation rate of a tissue increases the spontaneous 
mutation lead, with esophagus and skin having more 
mutations than brain and muscle. The largest presence 
of mutations was observed in two tissues, such as skin 
and lung, largely affected by environmental factors, 
























supporting the view that exogenous and endogenous 
factors cooperate to induce a high mutational load, a 
finding having important implications for understand-
ing the mechanisms of cancer development. According 
to the theory of Tomasetti and Vogelstein, the number 
of stem cell division would be a major determinant for 
the cancer risk of a given tissue. Since cell division can 
generate unavoidable mutations during DNA replica-
tion, the number of stem cell divisions can be consid-
ered equivalent to the number of mutations accumu-
lated at the level of driver genes [36, 37]. To evaluate 
this assumption, Lopez-Lazaro evaluated whether the 
variation in cancer risk among tissues could be ex-
plained by the number of gene mutations [36, 37]. To 
perform this analysis, whole genome sequencing data 
from more than 20 000 cancer samples were analyzed, 
together with the longest cancer registry in each conti-
nent and was determined the correlation between the 
average number of total gene mutations and the life-
time cancer across 33 cancer types [36, 37]. The results 
of this analysis showed that there is only a weak cor-
relation between these two parameters in each of the 
cancer registry studied; the correlation became stronger 
when gender-related cancers were excluded [36, 37]. 
According to these results it was concluded that cancer 
etiology can be better explained by the accumulation 
of stem cell divisions, rather than by the accumulation 
of gene mutations [36, 37]. To explain this finding, this 
author hypothesized that the simple analysis of nucleo-
tide DNA sequence mutations is limiting because stem 
cell divisions may cause other genomic alterations, such 
as gains and losses of DNA involved in cancer develop-
ment [36, 37].
It is of interest to note that the environmental factors 
and random mutational events are thought to target 
stem/progenitor cells inducing genetic abnormalities in 
these cells, responsible for cancer development in the 
context of a multistep cancerogenic process. In this con-
text, a recent fundamental study by Kucab and cowork-
ers provided a first compendium of mutational signatures 
induced in normal human-induced pluripotent stem cells 
by exposure to 79 known environmental carcinogens: a 
part of these experimentally-induced DNA abnormali-
ties resulted in mutational signatures similar to those ob-
served in spontaneous human tumors [38]. Importantly, 
this study underscores how the genome of human stem 
cells is vulnerable to environmental agents [38].
CANCER IMMUNOEDITING
In the year 2000, Hanahan and Weinberg published 
their fundamental review on cancer: the hallmarks of 
cancer [39], where they attempted to organize the con-
siderable complexities of cancer biology into six major 
hallmarks: sustained proliferative signaling, insensitiv-
ity/low-sensitivity to anti-growth signals, resisting cell 
death, illimited replicative potential, sustained angio-
genesis, and tissue invasion and metastasis. A decade 
later, an updating review [40] added two emerging hall-
marks: reprogramming energy metabolism and evad-
ing immune response, and two enabling traits: genome 
instability and mutation, and tumor-promoting inflam-
mation. These changes were strongly justified by the 
growing evidence about the role of immune system in 
cancer initiation, progression and metastasis [41]. Fur-
thermore, it was accumulated growing evidence that a 
potentiation of the immune mechanisms against cancer 
cells may represent a new fundamental strategy in the 
war against cancer.
The immune system plays a dual role in cancer develop-
ment: in fact, it can either suppress tumor growth by im-
munological destruction of cancer cells or limiting their 
outgrowth or, paradoxically, promote tumor progression 
through mechanisms involving the selection of tumor 
cells that are more capable of surviving in the context of 
an immunocompetent host or the promotion of condi-
tions in the tumor microenvironment that stimulate tu-
mor proliferation [41]. The complexity of these possible 
interactions between the immune system and cancer are 
globally known as “cancer immunoediting” [41].
The cancer immunoediting implies three different 
phases. The first phase involves the existence of immu-
nological mechanisms able to eliminate tumor cells dur-
ing their early stages of development. This step of active 
immunosurveillance implies that early tumor cells, not 
repaired by their intrinsic DNA repair mechanisms, are 
recognized by the immune system exploiting innate im-
mune mechanisms or adaptive immune response imply-
ing antigen recognition by dendritic cells and develop-
ment of specific CD4+ and CD8+ T cells, inducing the 
final lysis of tumor cells.
The first phase of tumor elimination by immune cells 
may not be complete and some tumor cells may persist 
and may reach an equilibrium condition with the im-
mune system, remaining in this condition for more or 
less long periods of time. 
The third phase is called the escape or the evasion 
stage during which cancer cells progress in their growth 
and, in many instances, acquire also the capacity to 
metastasize because they are not controlled by the im-
mune system. This escape of the tumor cells from the 
immunological control mechanisms is mainly related to 
cellular and molecular mechanisms that include either 
the suppression of the immune system by tumor cells or 
the acquisition of new genetic alterations that induce 
immune suppression. In this context, a fundamental 
mechanism of tumor escape is related to the ability of 
cancer cells to express cell surface immune checkpoint 
molecules, like those expressed on normal cells (such 
as PD-L1), and thus to suppress T cells at the level of 
immune checkpoints and, through this mechanism, to 
evade the immune system attack [42]. This mechanism 
of inhibition of the immunological reaction against tu-
mor cells is related to the overexpression by tumor cells 
of various surface molecules such as PD-L1, PD-L2, 
CD39, CD73 and CD47 that, interacting with their 
receptors expressed on immune cells, inhibit their func-
tion in the activation of the immune response [42]. The 
identification of these tolerance mechanisms has led 
to delineate the important role of two molecules, PD1 
and CTL-A4, that were recognized with the 2018 No-
bel Prize in Physiology or Medicine awarded by James 
Allison and Tasuku Honjo, and have led to the devel-
opment of new therapeutics that have revolutionized 
some areas of clinical oncology [42].
























Cancer immunotherapy based on immune checkpoint 
inhibitors can induce long lasting responses in patients 
with metastatic cancers of a wide range of histologies. 
Using this approach, the target of treatment shifted 
from the malignant cells to the host’s immune system, 
with the specific aim of obtaining the mobilization of 
immune cells able to recognize and eliminate tumor 
cells. A potential important feature of immunotherapy 
is the possible durability of response, at least in some 
patients, through the memory of the adaptive immune 
system, with induction of long-term survival. However, 
several mechanisms of resistance limit the broaden-
ing of the clinical applicability of these treatments, re-
lated to primary (tumor cells are intrinsically resistant 
to an immunotherapy strategy, a condition frequently 
observed), adaptive (the tumor cells are recognized by 
immune cells, but they protect their self by adapting to 
the immune attack) or acquired resistance (tumor cells 
initially respond to immunotherapy but after a period of 
time became resistant and relapsed) [43].
The development of innate and acquired resistance 
to immunotherapy represents an important barrier 
to treatment effectiveness and indicates the absolute 
need to better understand the mechanisms of cancer 
immunoediting. Thus, it appeared evident that it is of 
fundamental importance to stratify the tumor microen-
vironment, particularly in terms of its immunological 
and inflammatory components [44]. Thus, the Immu-
noscore is a system that using a combination of immu-
nohistochemistry and bulk tissue gene expression data 
allows an evaluation of the spatio-temporal dynamics of 
intratumoral immune cells and to stratify patients ac-
cording to immune-related criteria and subsequently to 
predict disease outcome [45, 46]. Thus, tumors can be 
stratified on the basis of genetic properties related to the 
malignant component, such as the mutational burden, 
and the presence or not of a T-cell inflamed gene sig-
nature, conditions predictive of a possible responsive-
ness to immunotherapy [44]. Thus, infiltrated-inflamed 
tumor immune microenvironments are the hallmark of 
immunologically “hot” tumors and are characterized by 
high infiltration of CD8+ lymphocytes expressing PD-1 
and leukocytes and tumor cells expressing the immune-
inhibitory PD-1 ligand PD-L1 [44].
The studies carried out in these last years in the field 
of cancer immunotherapy support the view that opti-
mal strategies to achieve tumor elimination will involve 
therapeutic combinations implying activation of T-cell 
anti-tumor response, suppression of immunosuppres-
sive signals present in the tumor microenvironment and 
sustaining the presence of T lymphocytes within the tu-
mor tissue [47]. A better understanding of the mecha-
nisms governing cancer immunoediting represents an 
absolute need to improve the comprehension of resis-
tance to cancer immunotherapy and to overcome such 
resistance [47].
ADVANTAGES AND LIMITATIONS 
OF TARGETED THERAPIES AND OF 
IMMUNOTHERAPY
Sequencing of individual patient tumor biopsies has 
revolutionized oncology, providing genetic informa-
tions on each specific tumor, offering the opportunity to 
understand the molecular changes that have occurred 
in each specific tumor. These studies have clearly shown 
that there is a consistent inter-tumor and intra-tumor 
heterogeneity, thus supporting the view that each pa-
tient’s individual tumor is a mixture of unique molecu-
lar irregularities that require an exclusive personalized 
therapeutic approach. The identification of some spe-
cific abnormalities in subsets of cancer patients has led 
to the development of new molecular targeted drugs. 
Over past two decades, biomarker-driven enrichment 
trials have represented a very important tool for the de-
velopment of new anticancer drugs. By the end of 2018, 
more than 30 drugs have been developed and approved 
for clinical use in conjunction with a biomarker test al-
lowing to select patients who can be treated with these 
drugs. A notable example of these development is given 
by colorectal cancer, a neoplasia for which numerous 
molecularly stratified treatment options are now avail-
able, guided by appropriated biomarkers; these new 
treatments resulted in a significant improvement in the 
survival of patients with metastatic colorectal cancer 
[48]. Comparably, studies in lung cancer patients have 
led to the identification of lung cancer subsets with spe-
cific molecular abnormalities, such as BRAF or EGFR 
mutations or ALK fusions that beneficiate from the 
development of specific targeted therapies in terms of 
progression-free survival or overall survival [49].
Most of these biomarker-guided drugs are marketed 
for specific cancer types; recently, two drugs were ap-
proved for all tumors displaying a specific molecular 
abnormality, Larotrectinib for patients with neuro-
trophic receptor tyrosine kinase (NTRK) gene fusion 
and Pembrolizumab (anti-PD-1) for the treatment of 
microsatellite-high (MSI-H) and mis-match-repair de-
ficient (dMMR) positive patients [50].
Unfortunately, after an initial response to targeted-
specific therapy, most tumors relapse due to the devel-
opment of resistance, related to various molecular and 
cellular mechanisms, actively explored for the various 
tumor types and for the various targeting agents; to by-
pass the mechanisms of resistance, specific targeting 
agents of first, second and third-generation with a dif-
ferential spectrum of inhibitory effects against different 
mutants of the targeted protein have been developed 
[51]. 
Many molecular abnormalities are observed in mul-
tiple tumor types and it was suggested according to se-
quencing data that each patient should be tailored ac-
cording to their specific molecular features. In a more 
extended view of this approach, corresponding to the 
so-called precision medicine in oncology, each patient 
should be optimally treated on the basis of molecular 
and cellular characteristics of the tumor and of its mi-
croenvironment and according also to some patient’s-
related features, such as genetics and lifestyle. Three 
recent studies report the results of three precision 
medicine trials in oncology that use molecular profiling 
assistance to select potentially appropriated therapy in 
patients with incurable refractory/recurrent metastatic 
cancer [52-54]. These studies involve also the use of 
innovative approaches for tumor characterization to 
























guide therapy [52-54]. The results of these three studies 
showed that the percentage of cancer patients respond-
ing to precision therapy guided by molecular profiling 
was low (comprised between 4-11%) and was improved 
when the patients had a higher proportion of molecular 
alterations [52-54].
However, several factors limit the impact of targeted 
therapy: this type of therapy is expensive and in many 
instances can be performed only in specialized centers; 
only a part of patients respond to these treatments and 
often for a limited time; the large majority of patients 
treated with targeted therapy necessitate of standard 
treatments; in many instances, the cost-benefit of tar-
geted therapy is questionable. Furthermore, the clini-
cal utility of molecular profiling for many oncological 
patients remains to be demonstrated.
In parallel to targeted therapies, in the last two de-
cades there was the consistent development of in im-
munotherapy studies in oncological patients, based 
on a new treatment strategy consisting to normalize 
in tumors the immune antitumor response, removing 
the inhibitory effects of physiological inhibitors of the 
immune response, such as PD-1/PD-L1, whose expres-
sion is enhanced in some tumors [55]. This normaliza-
tion approach achieved higher objective response rates 
in some cancer patients with a lower toxicity profile 
compared with historical approaches based on im-
munostimulation [55]. The tumors that obtain more 
benefit from modern cancer immunotherapy are repre-
sented by lung cancer, melanoma, kidney cancer, MSI-
H tumors, urothelial carcinoma, B-cell lymphomas and 
Hodgkin’s lymphomas [55]. However, only a minority 
of cancer patients achieve durable responses to cur-
rent immunotherapies, because only few patients have 
adoptive immune response to tumors inhibited by im-
munosuppressive mechanisms [55]. 
The limitations of cancer immunotherapy are related 
to the limited number of responding patients, the cost 
of the therapy requiring in responding patients long 
treatments and often the absence of valuable biomark-
ers predicting response to treatment [56]. Consistent 
efforts are ongoing to try to expand immunotherapy’s 
responding patients.
CONCLUSIONS: TUMOR PREVENTION  
IS A PIVOTAL STRATEGY IN THE WAR 
AGAINST CANCER
Although a great debate remains open about the pro-
portion of cancers related to non-preventable, random 
genetic events, it is evident that tumors can be distin-
guished into two groups: (a) tumors in which driven 
mutations are caused by environmental factors; (b) tu-
mors in which there is a large proportion of mutations 
of driver genes related to random genetic events (R mu-
tations). The prevention strategy in these two types of 
tumors must be different: in tumors largely related to 
environmental factors, such as lung cancer, melanoma 
of the skin and cervical cancer, primary prevention is 
the best strategy aiming to drastically reduce cancer in-
cidence through smoking cessation, avoidance of UV 
radiation exposures and vaccination against papillo-
mavirus, respectively; in tumors that display a signifi-
cant proportion of R type mutations, such as prostate, 
breast, colon and pancreas cancers, in which only a part 
of cases can be related to environmental risks, the opti-
mal strategy consists in  secondary prevention, aiming 
to the detection and intervention at early time during 
disease evolution. It is evident that harmonization be-
tween epidemiologic and molecular studies is strictly 
required to improve cancer prevention strategies, that 
represent an absolute priority to reduce cancer inci-
dence and mortality. 
The progresses in the understanding the cellular and 
molecular basis of cancer initiation and progression 
have been very remarkable in these last years, but not 
paralleled by a proportional improvement in the im-
provement of the medical anticancer therapies.
The increased incidence of cancer reflects the im-
provements in life expectancy, increasing the chances 
that in each individual this pathology occurs. It was es-
timated by the International Agency for Research on 
Cancer (IARC, Lyon, France) that the annual incidence 
of new cases of cancer will increase from 18.1 million in 
2018 to 29.4 million in 2040. The cost of this continu-
ously growing global cancer burden for national health-
care systems is tremendous, even for most economically 
developed countries. It is evident that the first priority 
to meet this problem, even in economic terms, consists 
in developing more efficacious and more accepted sys-
tems of primary and secondary cancer prevention at the 
level of global population worldwide. This development 
will need a real cooperation between scientific and po-
litical authorities to converge to common purpose in 
global health and to try to bypass the historical paradox 
of disease prevention: celebrated in principle, resisted 
in practice [57].
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